Ungar R, Wu L, MacLeod S, Tkatch R, Huang J, Kraemer S, Schaffer J, Yeh C. The impact of COVID-19 on older adults: results from an annual survey. Geriatr Nurs. 2022 Mar;44:131-6. doi: 10.1016/j.gerinurse.2022.01.010
Doherty K, Barry M, Belisario JM, Morrison C, Car J, Doherty G. Personal information and public health: design tensions in sharing and monitoring wellbeing in pregnancy. Int J Hum Comput Stud. 2020 Mar;135:102373. doi: 10.1016/j.ijhcs.2019.102373
John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
MacLeod S, Musich S, Kraemer S, Wicker E. Practical non-pharmacological intervention approaches for sleep problems among older adults. Geriatr Nurs. 2018 Sep;39(5):506-12. doi: 10.1016/j.gerinurse.2018.02.002
Tkatch R, Musich S, MacLeod S, Kraemer S, Hawkins K, Wicker ER, Armstrong DG. A qualitative study to examine older adults' perceptions of health: Keys to aging successfully. Geriatr Nurs. 2017 Nov;38(6):485-90. doi: 10.1016/j.gerinurse.2017.02.009
MacLeod S, Musich S, Gulyas S, Cheng Y, Tkatch R, Cempellin D, Bhattarai GR, Hawkins K, Yeh CS. The impact of inadequate health literacy on patient satisfaction, healthcare utilization, and expenditures among older adults. Geriatr Nurs. 2017 Jul;38(4):334-41. doi: 10.1016/j.gerinurse.2016.12.003
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
MacLeod S, Musich S, Hawkins K, Alsgaard K, Wicker ER. The impact of resilience among older adults. Geriatr Nurs. 2016 Jul;37(4):266-72. doi: 10.1016/j.gerinurse.2016.02.014
White MV, Silvia S, Hollis K, Wooddell M, Hogue S. Differences in anaphylaxis-related risks by school grade level: findings from the EpiPen4Schools® survey. Poster presented at the 2015 ASCIA Conference; September 2015. Adelaide, Australia. [abstract] Intern Med J. 2015 Sep 3; 45(Suppl 4):3. doi: 10.1111/imj.12869
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.